Vimarsana
Biggest News Aggregation in the World

Page 22 - Double Blind Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Double Blind Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Double Blind Study Today - Breaking & Trending Today

Gut Signature for Treatment-Resistant Schizophrenia? - Vimarsana News

Gut Signature for Treatment-Resistant Schizophrenia?

Adults with resistant schizophrenia have significant gut microbiome differences vs their counterparts who respond to treatment, a new finding that may be driven by clozapine treatment.

Total Abstinence Not the Only Treatment Goal in SUD - Vimarsana News

Total Abstinence Not the Only Treatment Goal in SUD

In patients with SUD, even slight reductions in drug use are linked to better outcomes, suggesting abstinence should not be the only goal of treatment, a new analysis showed.

Biogen's Abandonment of AD Drug No Surprise, Experts Say - Vimarsana News

Biogen's Abandonment of AD Drug No Surprise, Experts Say

More than 2 years after its controversial accelerated FDA approval, Biogen says it will halt development and commercialization of aducanumab and focus on lecanemab.

Once-Weekly Insulin Better Than Daily in Type 2 Diabetes - Vimarsana News

Once-Weekly Insulin Better Than Daily in Type 2 Diabetes

Once-weekly insulin icodec reduced A1c levels the same or better than once-daily glargine and degludec.

Targeting mTOR Shows Promise in Cutaneous Sarcoidosis - Vimarsana News

Targeting mTOR Shows Promise in Cutaneous Sarcoidosis

Vienna researchers reported that 7 of 10 patients treated with systemic sirolimus had noted improvements in skin lesions, which continued for up to 2 years of follow-up.